The UK genetics and animal health firm Benchmark Holdings announced a pair of key departures from its management positions due to take place in the coming weeks, as it moves from a research to commercial footing.

Firstly, chief scientific officer Alex Raeber will be stepping down from his role on July 31, the company said. Raeber has reportedly led the review of the company's new product pipeline, as well as reorganizing Benchmark's in-house trial facilities. Raeber's departure comes as the firm ends its R&D investment phase, it said [...]